EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Targeting HER2 in Nuclear Medicine for Imaging and Therapy

Adriana V F Massicano, Bernadette V Marquez-Nostra, Suzanne E Lapi

Molecular Imaging · 01.01.2018 · 17

DOI: 10.1177/1536012117745386 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Imaging, online erschienen am 23.01.2018. Verfasst von Adriana V F Massicano und 2 weiteren Autor:innen. Beteiligte Einrichtung: 1 Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, USA. Hauptthemen laut MEDLINE: Molecular Imaging, Nuclear Medicine. Die Arbeit wurde bisher 75-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Since its discovery, the human epidermal growth factor 2 (HER2) has been extensively studied. Presently, there are 2 standard diagnostic techniques to assess HER2 status in biopsies: immunohistochemistry and fluorescence in situ hybridization. While these techniques have played an important role in the treatment of patients with HER2-positive cancer, they both require invasive biopsies for analysis. Moreover, the expression of HER2 is heterogeneous in breast cancer and can change over the course of the disease. Thus, the degree of HER2 expression in the small sample size of biopsied tumors at the time of analysis may not represent the overall status of HER2 expression in the whole tumor and in between tumor foci in the metastatic setting as the disease progresses. Unlike biopsy, molecular imaging using probes against HER2 allows for a noninvasive, whole-body assessment of HER2 status in real time. This technique could potentially select patients who may benefit from HER2-directed therapy and offer alternative treatments to those who may not benefit. Several antibodies and small molecules against HER2 have been labeled with different radioisotopes for nuclear imaging and/or therapy. This review presents the most recent advances in HER2 targeting in nuclear medicine focusing on preclinical and clinical studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Molecular ImagingNuclear MedicineHumansRadiopharmaceuticalsErb-b2 Receptor Tyrosine Kinases

Stichwörter der Autor:innen

HER2 imagingHER2-positive cancerPET/CTSPECT/CTbreast cancerhuman epidermal growth factor 2molecular imagingreceptor radionuclide therapy

Substanzen

RadiopharmaceuticalsErb-b2 Receptor Tyrosine Kinases

Autor:innen und Institutionen

  • 1 Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, USA.
  • 2 Department of Radiology and Biomedical Imaging, Yale University, New Haven, CT, USA.

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Massicano, A. V. F., Marquez-Nostra, B. V., & Lapi, S. E. (2018). Targeting HER2 in Nuclear Medicine for Imaging and Therapy. Molecular Imaging, 17. https://doi.org/10.1177/1536012117745386

Vancouver

Massicano AVF, Marquez-Nostra BV, Lapi SE. Targeting HER2 in Nuclear Medicine for Imaging and Therapy. Molecular Imaging. 2018;17. doi:10.1177/1536012117745386

BibTeX
@article{Massicano2018,
  author = {Massicano, Adriana V F and Marquez-Nostra, Bernadette V and Lapi, Suzanne E},
  title = {Targeting HER2 in Nuclear Medicine for Imaging and Therapy},
  journal = {Molecular Imaging},
  year = {2018},
  volume = {17},
  doi = {10.1177/1536012117745386}
}
Kostenlos starten →